Olema Pharmaceuticals, Inc. financial data

Symbol
OLMA on Nasdaq
Location
San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1078% % 16%
Debt-to-equity 10% % -13%
Return On Equity -42% % 22%
Return On Assets -38% % 21%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68,659,923 shares 20%
Common Stock, Shares, Outstanding 68,652,730 shares 20%
Entity Public Float $454,300,000 USD 85%
Common Stock, Value, Issued $7,000 USD 75%
Weighted Average Number of Shares Outstanding, Basic 85,732,221 shares 50%
Weighted Average Number of Shares Outstanding, Diluted 85,732,221 shares 50%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $146,776,000 USD 24%
General and Administrative Expense $18,606,000 USD 4.4%
Operating Income (Loss) $165,382,000 USD -22%
Nonoperating Income (Expense) $15,425,000 USD 17%
Net Income (Loss) Attributable to Parent $149,957,000 USD -22%
Earnings Per Share, Basic -1 USD/shares 14%
Earnings Per Share, Diluted -1 USD/shares 14%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $35,260,000 USD -1.8%
Marketable Securities, Current $293,700,000 USD 64%
Cash, Cash Equivalents, and Short-term Investments $329,000,000 USD 53%
Assets, Current $334,329,000 USD 53%
Property, Plant and Equipment, Net $486,000 USD -43%
Operating Lease, Right-of-Use Asset $1,419,000 USD -9.4%
Other Assets, Noncurrent $15,000 USD -6.2%
Assets $352,453,000 USD 53%
Accounts Payable, Current $3,474,000 USD 29%
Employee-related Liabilities, Current $406,000 USD -67%
Liabilities, Current $41,655,000 USD 36%
Operating Lease, Liability, Noncurrent $310,000 USD -45%
Liabilities $44,965,000 USD 44%
Accumulated Other Comprehensive Income (Loss), Net of Tax $526,000 USD 13%
Retained Earnings (Accumulated Deficit) $551,496,000 USD -37%
Stockholders' Equity Attributable to Parent $307,488,000 USD 55%
Liabilities and Equity $352,453,000 USD 53%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $43,979,000 USD -87%
Net Cash Provided by (Used in) Financing Activities $222,000 USD -97%
Net Cash Provided by (Used in) Investing Activities $45,083,000 USD -124%
Common Stock, Shares Authorized 490,000,000 shares 0%
Common Stock, Shares, Issued 68,652,730 shares 20%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $88,840,000 USD -155%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35,260,000 USD -1.8%
Deferred Tax Assets, Valuation Allowance $104,502,000 USD 46%
Deferred Tax Assets, Gross $105,089,000 USD 45%
Operating Lease, Liability $1,478,000 USD -13%
Payments to Acquire Property, Plant, and Equipment $153,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $149,895,000 USD -23%
Lessee, Operating Lease, Liability, to be Paid $1,554,000 USD -14%
Operating Lease, Liability, Current $1,168,000 USD 2.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two $69,000 USD -74%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,171,000 USD -5.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $76,000 USD -33%
Deferred Tax Assets, Operating Loss Carryforwards $60,600,000 USD 36%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $1,238,000 USD 11%
Additional Paid in Capital $858,451,000 USD 43%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $128,000 USD 45%
Share-based Payment Arrangement, Expense $19,643,000 USD -4.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%